Bayer's Asundexian, a stroke treatment, received US regulatory approval.
Approval was based on a clinical trial showing that adding Asundexian to
antiplatelet therapy reduced recurrent stroke risk by 26% without increasing
major bleeding. The decision provides a boost to Bayer's pharma business amid
growing generic pressure on some core drugs.
